RA
FBIO icon

Rosalind Advisors’s Fortress Biotech FBIO Stock Holding History

Rosalind Advisors’s Portfolio FBIO Stock Details FBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-502,828
Closed -$727K – 46
2024
Q3 		$727K Sell
502,828
-104,969
-17% -$200K 0.47% 25
2024
Q2 		$1.04M Hold
607,797
– – 0.8% 26
2024
Q1 		$1.22M Hold
607,797
– – 1.14% 25
2023
Q4 		$1.83M Buy
+607,797
New +$1.61M 1.51% 21

Other funds holding FBIO

Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAM
PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
SAM
Shikiar Asset Management New York $396M AUM 41.06% 1-Year Est. Return
KAS
Kestra Advisory Services Austin, Texas $31B AUM 28.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Rosalind Advisors's FBIO Position: Q4 2024 in Review

Rosalind Advisors sold out of Fortress Biotech (FBIO) in Q4 2024, closing a stake of 502,828 shares — an estimated $727K sold.

Rosalind Advisors first reported a position in FBIO in Q4 2023 and held it in 4 quarters. The position peaked at $1.83M in Q4 2023. 53 funds tracked by Wall St. Rank hold FBIO as of Q4 2024.

  • Rosalind Advisors reported no remaining Fortress Biotech position as of Q4 2024 after selling out during the quarter.
  • Rosalind Advisors sold 502,828 Fortress Biotech shares in Q4 2024, an estimated $727K.
  • Rosalind Advisors first reported a position in Fortress Biotech in Q4 2023 and held it in 4 quarters.
  • Rosalind Advisors's Fortress Biotech position peaked at $1.83M in Q4 2023.
  • 53 funds tracked by Wall St. Rank held Fortress Biotech as of Q4 2024.

Based on Rosalind Advisors's 13F filing for Q4 2024, filed 11 Feb 2025.